|
|
||||||||
, IL-1ß, and IFN
on Human Conjunctival Epithelial Cell Receptor Expression and Chemokine Release
1From the Departments of Medicine and 3Ophthalmology and Visual Sciences, School of Medicine, University of Wisconsin-Madison, Madison, Wisconsin.
| Abstract |
|---|
|
|
|---|
, IL-1ß, and IFN
on chemokine release (IL-8, regulated on activation normal T-cell expressed and secreted [RANTES]) and surface receptor expression (intercellular adhesion molecule [ICAM]-1, and HLA-DR, -DP, and -DQ) were examined. METHODS. Conjunctival epithelial cells were isolated from cadaveric conjunctival tissues and cultured in 24-well plates until almost confluent. Recombinant cytokines (0.00550 ng/mL) were added, alone or in various combinations, 24 hours before harvesting of supernates for ELISAs and cells for flow cytometry.
RESULTS. TNF
, IL-1ß, and IFN
had distinctive individual and combined effects on the parameters tested. Although TNF
and IL-1ß had similar and synergistic effects on increasing expression of ICAM-1, IL-1ß was a more potent upregulator of the release of IL-8 than was TNF
. Upregulation of IL-8 was additive when IL-1ß was combined with TNF
. Neither TNF
nor IL-1ß increased expression of HLA. In contrast, IFN
was a potent upregulator of both surface receptors (ICAM-1 and HLA) but IFN
alone had no effect on mediator release (IL-8 and RANTES). Release of RANTES required two cytokine signals, with IFN
and TNF
being the most potent combination.
CONCLUSIONS. Knowledge of the differential and combined effects of proinflammatory cytokines on conjunctival epithelial cells allows better understanding of ocular inflammation.
It has been demonstrated in multiple tissues, including the conjunctival epithelium, that stimulation of epithelial cells through proinflammatory cytokines such as TNF
, IL-1ß, and IFN
results in upregulation of surface receptor expression and mediator release.2 3 4 5 6 7 8 11 12 There is evidence for participation of these proinflammatory cytokines in the pathogenesis of acute and chronic ocular inflammation. Specifically, TNF
concentrations in tears are increased after allergen provocation and the ratio of TNF
to IFN
concentrations is increased in tears from allergic subjects compared with nonallergic subjects.13 14 Both TNF
and IL-1 (
and ß) are also increased in the conjunctival epithelium of patients with Sjögren syndrome KCS, and the levels of IL-1 RNA directly correlate with intensity of corneal fluorescein staining and decreased conjunctival goblet cell density.4 15 This increase in IL-1 is accompanied by a decrease in anti-inflammatory IL-1 receptor antagonist (IL-1ra). In ocular allergic inflammation, IL-1 also appears to play a role, in that IL-1ra suppresses allergic eye disease in a murine model for allergic conjunctivitis.16 In addition, T cells expressing IFN
have been reported in atopic keratoconjunctivitis (AKC), vernal keratoconjunctivitis (VKC), and Sjögren syndrome.17 18 19 20
Although these studies provide insight, the specific mechanisms for regulation of these processes in conjunctival epithelial cells are not fully understood. Therefore, to investigate further the individual and combined effects of TNF
, IL-1ß, and IFN
on primary cultures of human conjunctival epithelial cells release of IL-8 and RANTES and surface expression of ICAM-1 and HLA, the following studies were conducted.
| Methods |
|---|
|
|
|---|
was obtained from R&D Systems (Minneapolis, MN), recombinant human IL-1ß from BioSource International (Camarillo, CA), and recombinant human TNF
from Genzyme Diagnostics (Cambridge, MA). The IL-8 and RANTES ELISAs were obtained from BioSource International, Inc. The Tyrode physiological salt solution plus gelatin (TG) used in these studies consisted of (mM) NaCl, 137; KCl, 2.6; NaH2PO4, 0.35; NaHCO3, 11.9; glucose, 5.5; and gelatin 1 g/L, adjusted to pH 7.4 with HCl. TGCM is TG with added CaCl2 (2 mM) and MgCl2 (1 mM). The density gradient (Percoll; Sigma Chemical Co.) stock solution was prepared by mixing the commercial solution and 10x HEPES buffer plus dH2O to obtain an osmolality of 285 mOsm/kg H2O. The desired density of the gradient was prepared by mixing the stock solution with TG. HBSS-BAP, used as a flow cytometry staining buffer, consisted of HBSS, BSA (1 g/L), NaN3 (0.5 g/L), and phenylmethylsulfonyl fluoride (18 mg/L in 4 mL ethanol).
Epithelial Cell Isolation, Purification, and Culture
Modifications of previously reported methods for obtaining purified conjunctival epithelial cells were used in these studies.21 Briefly, human conjunctival tissue was obtained from organ-tissue donors (810 sets of tissue per experiment obtained through the Lions Eye Bank of Wisconsin, a nationwide network of eye banks and the National Disease Research Interchange). Upper and lower bulbar conjunctivae aseptically collected within 8 hours after death (average time, 4.5 hours) were transported in corneal preservation medium (Dexsol; Chiron Ophthalmics, Irvine, CA) and stored at 4°C for up to 5 days. Eight to 10 sets of tissue weighing 4 to 5 g were used per experiment. Hyaluronidase and collagenase were used to digest tissue. The digestion process (30 minutes at 37°C on a rotating shaker) was first performed at a low concentration of enzymes (two digests at 200 U/g in a 10-mL final volume). This was followed by tissue digestion at a high concentration of enzymes (three to six digests at 2000 U/g in a 10-mL final volume). Each digest was followed by washing of the enzyme-treated tissue (with TGCM) over a 100-µm nylon mesh filter to collect freed cells. After the digestion procedure, the freed cells were pelleted, pooled, resuspended in TG, and layered over a single-density gradient (1.041 g/mL; Percoll; Sigma Chemical Co.) and centrifuged (500g, 20 minutes). The top cell layer (epithelial cells) was harvested, washed, and resuspended in KGM (without hydrocortisone, at a concentration of 1 x 106 cells/mL) and transferred to collagen/fibronectin-coated 24-well plates (0.5 mL/well) for culture at 37°C. Media were changed every 48 hours until confluence. Purity was determined by flow cytometric analysis of mouse anti-human pancytokeratin-FITC antibody staining of fixed and permeabilized cells, as previously reported.21
Treatment of Conjunctival Epithelial Cell Monolayers
Conjunctival epithelial cells (one to two passages) were cultured on 24-well plates until almost confluent (2448 hours after passage). Recombinant TNF
, IL-1ß, and/or IFN
(0.00550 ng/mL) were added to the cultures, alone or in various (all) combinations for 24 hours at 37°C. After 24 hours, the supernates were collected and stored at -70°C until analysis.
Flow Cytometric Analysis of Surface Receptors on Conjunctival Epithelial Cells
After the supernatants were removed, the epithelial cell monolayers were harvested with trypsin-EDTA and resuspended in 220 µL HBSS-BAP (20 µL removed for cell counts and 200 µL used for staining). Two-color staining was used to measure surface HLA (HLA-DR, -DP, and -DQ) and ICAM-1 expression. Each tube of 100 µL of viable cells (not fixed, 3.05.0 x 104 cells/tube) were stained with mouse anti-human pan-HLA-FITCconjugated antibody and mouse anti-human ICAM-1-PEconjugated antibody or mouse IgG2a-PEconjugated antibody isotype control and mouse IgG2a-FITCconjugated antibody isotype control, using the manufacturers recommended amounts (10 µL/tube). The stained cells were incubated on ice for 30 minutes, washed and resuspended in 300 µL/tube of HBSS-BAP for analysis. Propidium iodide was added to each tube to determine viability. Data were acquired with a flow cytometer (FACScan; BD Biosciences) operated with the accompanying software (CellQuest; BD Biosciences). The data, based on gating of viable cells only (10,000 viable cells counted/tube), was analyzed geometrically (WinMDI; http://www.facs.scripps.edu; the Scripps Research Institute, La Jolla, CA). Data are reported as percentage of positive-staining cells.
Measurement of IL-8 and RANTES Release from Conjunctival Epithelial Cells
The levels of IL-8 and RANTES in the epithelial cell supernates were determined by commercial ELISA according to the manufacturers instructions. Cell counts were performed on the cells harvested as above for flow cytometric analysis (Coulter Counter; Model ZM; Beckman Coulter Corp., Miami, FL) to determine the number of epithelial cells per milliliter. Data are reported as the concentration of cytokines per million cells.
Statistical Analyses
Data were computer analyzed (SAS software; SAS Institute, Cary, NC). A general linear-model analysis of variance (ANOVA) with preplanned comparisons was computed to generate two-tailed probabilities. The Fisher least-significant-difference test was used to make appropriate post-ANOVA comparisons. P ≤ 0.05 was considered statistically significant. Potential cytokine interactions were evaluated by comparing the calculated additivity (response to cytokine x alone + response to cytokine y alone) with the experimental additivity (response to simultaneous stimulation with cytokine x and cytokine y) for each combination of concentrations tested. Interactions of cytokines were defined as follows22 : additive when the calculated additivity was not significantly different from the experimental additivity; nonadditive when the experimental additivity was significantly less than the calculated additivity; or synergistic when the experimental additivity was significantly greater than the calculated additivity. All data are presented as the mean ± SEM of results from four to seven separate experiments.
| Results |
|---|
|
|
|---|
treatment (up to 90% positive cells) compared with IL-1ß or TNF
treatment (up to 45% positive cells for both; Fig. 1B ). When TNF
and IL-1ß were combined, ICAM-1 expression was increased over that induced by either cytokine alone at 5 and 50 ng/mL (all combinations were significantly different compared with either cytokine alone); however, the effect was subadditive. This is illustrated in the bar graph in Figure 1C , which shows the individual and combined effect of stimulation with 5 ng/mL TNF
and IL-1ß on expression of ICAM-1, compared with the calculated combined effect. The experimental combined effect was significantly less than the calculated combined effect (see the Methods section). A similar effect was observed at other dose combinations (data not shown). When either IL-1ß or TNF
was combined with IFN
treatment, no effect on ICAM-1 expression was observed compared with IFN
treatment alone.
|
treatment in a concentration-dependent manner, but not by TNF
or IL-1ß treatment (Fig. 2B) . No synergistic or additive effects on conjunctival epithelial cell expression of HLA were observed with any combination of cytokines. It should also be noted that at the 50 ng/mL concentration of IFN
, some loss of viability (10%15%) was observed, by using propidium iodide uptake.
|
(Fig. 3A) . IFN
treatment alone did not increase the IL-8 level above that of constitutive release. An effect of IFN
on IL-8 release (increased) was observed only when IFN
(0.5 and 5.0 ng/mL) was combined with IL-1ß (50.0 ng/mL; data not shown). TNF
and IL-1ß together had an additive effect on release of IL-8 at all combinations of doses. The bar graph in Figure 3B is representative of the additive effect on release of IL-8 observed at 5 ng/mL IL-1ß and TNF
. In Figure 3B , the individual and combined effect of stimulation with 5 ng/mL TNF
and IL-1ß on IL-8 release is compared with the calculated combined effect, which is the same as the experimental combined effect (see the Methods section). A similar effect was observed at other dose combinations (data not shown).
|
and either TNF
or IL-1ß being the most potent combinations. Figure 4 illustrates the effect of TNF
and IFN
together on release of RANTES (IL-1ß and IFN
together produced equivalent results). Between TNF
and IFN
and between IL-1ß and IFN
, there was a trend toward a synergistic interaction on release of RANTES that did not reach statistical significance. It is also important to note that IL-8 was released at much greater concentrations than RANTES (31100 ng/million cells versus 0 to 18 pg/million cells, respectively).
|
| Discussion |
|---|
|
|
|---|
, IL-1ß, and IFN
have individual and combined effects on conjunctival epithelial cells in vitro. It is well known that TNF
and IL-1ß promote activation of some of the same genes that modulate inflammation. In these studies, we observed that, although treatment with TNF
and IL-1ß resulted in similar upregulation of ICAM-1 expression, IL-1ß was a more effective potentiator of IL-8 release. Furthermore, when TNF
and IL-1ß were applied in combination, the effect was additive for release of IL-8. Cooperation between proinflammatory cytokines has been well documented in the literature. Possible mechanisms include signaling through separate pathways leading to coordinated binding of multiple transcription factors to the IL-8 gene and/or posttranscriptional regulation; however, the latter mechanism is not commonly reported in cooperative interactions between cytokines.23 Although upstream signaling from their respective receptors is distinctly different, TNF
and IL-1ß overlap in activation of downstream transcription factors. In the case of the IL-8 gene, transcriptional regulation by TNF
and IL-1ß can involve multiple transcription factors. In some cell types, including epithelial cell lines, TNF
signaling primarily involves activation of nuclear factor (NF)-
B and activator protein (AP)-1, whereas IL-1ß primarily activates NF-
B and nuclear factor (NF)-IL6.24 NF-
B binding to the promoter appears to be essential for IL-8 gene activation, but it must be combined with binding of either AP-1 or NF-IL6.24 25 The literature suggests that NF-IL6 potently enhances IL-8 promoter activity through a physical interaction with NF-
B at the promoter.26 Consequently, it is not surprising that IL-1ß is a more potent stimulator of the release of IL-8 (because it activates NF-IL6) and that simultaneous stimulation with TNF
and IL-1ß would result in enhanced release.
Combined stimulation of conjunctival epithelial cells with TNF
and IL-1ß also enhanced expression of ICAM-1, but the net effect was subadditive. This implies that the pathway to upregulation of ICAM-1 by these two cytokines is shared or redundant, which has been demonstrated to be the case in other cell types. The major signal transduction pathway in activation of the ICAM-1 promoter for both TNF
and IL-1ß converges at the level of NF-
B activation, which is sufficient for activation of expression of the ICAM-1 gene.27
In contrast, IFN
was found to be ineffective in promoting release of IL-8 from conjunctival epithelial cells, but was the most potent upregulator of surface receptor expression. In fact, IFN
was the only cytokine effective in upregulation of HLA. Upregulation of ICAM-1 and HLA by IFN
primarily occurs through a pathway that is not dependent on NF-
B. IFN
-responsive genes are activated through both IFN regulatory factor (IRF)-1 and signal transducer and activator of transcription (STAT)-1 transcription factors, which have not been shown to play important roles in activation of the IL-8 gene.24 26 In our model, we did not observe a synergistic or additive effect of cytokine combinations on HLA protein expression over 24 hours. Although some studies have shown that TNF
is synergistic with IFN
for upregulation of MHC class II gene expression in some cell types, the mechanisms vary.28 29 30 However, there is consensus that although TNF
modulates MHC class II gene expression, TNF
alone is not sufficient to activate the class II transactivator, an IFN
-responsive gene that is the master regulator of MHC class II molecules.28 29 30 31
Our data demonstrate a cooperative effect of inflammatory cytokines in induction of the release of RANTES from conjunctival epithelial cells. Various studies have demonstrated that both individual and combined stimulation with IFN
, TNF
, and/or IL-1ß can induce release of RANTES from a variety of cell types.32 33 34 However, in our study, none of the three cytokines (IFN
, TNF
, or IL-1ß) when added individually was effective in promoting expression of RANTES, whereas any combination of cytokines resulted in some release (with IFN
combined with either TNF
or IL-1ß being the most potent combination). Expression of human RANTES mRNA is differentially regulated based on stimulus and cell type. Furthermore, in some models, expression of RANTES is delayed, whereas, in others, it can be immediate and transient. Given the low concentrations of RANTES protein released in conjunctival epithelial cell supernatants (picograms per 106 cell range, in contrast to nanograms per 106 for IL-8), it is possible that the individual cytokines stimulate expression of RANTES, but the concentration of protein released in 24 hours is too low to detect, or that activation of the RANTES gene is delayed. Enhanced activation of the RANTES gene by combinations of cytokines has been reported.32 34 For example, activation of the RANTES gene is enhanced by a combination of TNF
and IFN
due to a cooperative effect of activation of both NF-
B and IRF-1.32
Integrating these in vitro findings with information gained from in vivo studies and our knowledge of the biological activities of the components measured has the potential to contribute significantly to our understanding of the pathogenesis of ocular surface inflammation. Discerning the cellular sources of cytokines and modes of activation of these cells is also critical to determining pharmacological targets. In allergic eye disease, the inflammatory cytokines TNF
, IL-1ß, and IFN
are present, yet their cellular sources have not been specifically identified.12 13 14 15 16 17 During acute ocular allergic disease, conjunctival mast cells are probably the initial source of the proinflammatory cytokines TNF
and IL-1ß. We have demonstrated that anti-IgE antibody challenge of purified human conjunctival mast cells results in TNF
release in a concentration-dependent manner.35 Supernatants from anti-IgEactivated conjunctival mast cells upregulate conjunctival epithelial cell ICAM-1 expression and release of IL-8.2 3 Furthermore, the mechanism for mast cell supernatantmediated upregulation of ICAM-1 was determined to be TNF
specific. This was demonstrated in studies using blocking antibody to TNF
and inhibition by the mast cell stabilizer, olopatadine, which also inhibits release of histamine, tryptase, and prostaglandin D2 (PGD2) from conjunctival mast cells.2 36 Mast cells are also believed to be an important source of IL-1ß, and preliminary data (message expression and intracellular protein immunostaining) from our laboratory with conjunctival mast cells support this (Stahl et al., unpublished data, 2002). Therefore, in ocular allergic inflammation, simultaneous release of TNF
and IL-1ß from mast cells could explain the increase in IL-8 that has been reported in epithelial cells on the ocular surface in AKC and VKC.9 In VKC, IL-8 levels in supernates obtained from the ocular surface correlate with numbers of infiltrating eosinophils and neutrophils and severity of corneal lesions.37
As mentioned, TNF
, IL-1 (
and ß), and IL-8 are increased in the conjunctival epithelium of patients with Sjögren syndrome KCS. Several studies have suggested that the lacrimal gland acinar cell is an important source of IL-1ß, which is also increased in tear fluid in dry-eye disease.15 Furthermore, the levels of IL-1 and IL-8 RNA directly correlate with indicators of disease severity.4 15 Our studies indicate that this may be in part to because IL-1ß is a potent stimulator of the release of IL-8 from conjunctival epithelial cells.
Although it has been reported that mast cells can release IFN
, to date we have not confirmed this with conjunctival mast cells. In chronic ocular surface inflammation, T cells are a likely major source of IFN
.16 17 As previously mentioned, T cells expressing IFN
have been reported in AKC, VKC, and Sjögren syndrome.17 18 19 20 IFN
is critical for upregulation of surface receptors required for cell-to-cell interactions including migration and antigen presentation. In fact, the antigen-presenting potential of human conjunctival epithelium has been suggested by the concomitant upregulation of CD40 (coreceptor for T-cell activation and antigen presentation) and HLA in vitro.38 Antigen-presenting capability of corneal epithelial cells and lacrimal acinar cells has been demonstrated.39 40 Additional studies suggest a role for signaling through ICAM/leukocyte function-associated antigen (LFA)-1 interactions in costimulation of T cells.41 In vitro it has been shown that retinal pigment epithelial cells are capable of presenting bacterial superantigens to T cells through an interaction involving ICAM-1.42 These interactions between epithelial cells and IFN
-secreting T cells may be important components in the maintenance of chronic ocular inflammation. Furthermore, the results presented herein suggest the combination of IFN
with either TNF
or IL-1ß in vivo would result in release of RANTES, potentially explaining the persistent T-cell infiltration that is characteristic of ocular inflammatory conditions that become chronic, such as AKC and Sjögren syndrome KCS. In addition, it has been hypothesized that IFN
contributes to inhibition of mucus production, as has been shown in airway inflammation.43
These studies demonstrate the importance of individual and combined effects of cytokines present during ocular inflammatory processes on conjunctival epithelial cell activation. Selective changes in the balance of proinflammatory mediators, as the result of treatment, could have potential importance in managing ocular inflammation.
| Footnotes |
|---|
Supported in part by Alcon Labs, Fort Worth, Texas, an unrestricted grant from Research to Prevent Blindness, and National Eye Institute Grant EY12526.
Submitted for publication July 16, 2002; revised October 8, 2002; accepted November 7, 2002.
Disclosure: J.L. Stahl, None; E.B. Cook, None; F.M. Graziano, Alcon Labs (F); N.P. Barney, Alcon Labs (F)
The publication costs of this article were defrayed in part by page charge payment. This article must therefore be marked "advertisement" in accordance with 18 U.S.C.
1734 solely to indicate this fact.
Corresponding author: James L. Stahl, University of Wisconsin-Madison, H6/361 Clinical Science Center, 600 Highland Avenue, Madison, WI 53792; jlstahl{at}medicine.wisc.edu.
| References |
|---|
|
|
|---|
B synergistically activate transcription of the inflammatory cytokines, interleukin 6 and interleukin 8 Proc Natl Acad Sci USA 20,10193-10197
and interferon-
synergistically activate the RANTES promoter through nuclear factor
B and interferon regulatory factor 1 (IRF-1) transcription factors Biochem J 350,131-138
plus TNF-
and inhibition by IL-4 and IL-13 J Immunol 154,1870-1878[Abstract]
release from human conjunctival mast cells Ann Allergy Asthma Immunol 84,505-508
This article has been cited by other articles:
![]() |
E. B. Cook, J. L. Stahl, A. M. Brooks, F. M. Graziano, and N. P. Barney Allergic tears promote upregulation of eosinophil adhesion to conjunctival epithelial cells in an ex vivo model: inhibition with olopatadine treatment. Invest. Ophthalmol. Vis. Sci., August 1, 2006; 47(8): 3423 - 3429. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Narayanan, W. L. Miller, and A. M. McDermott Conjunctival cytokine expression in symptomatic moderate dry eye subjects. Invest. Ophthalmol. Vis. Sci., June 1, 2006; 47(6): 2445 - 2450. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |